General Dermatology

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dermatology Times is looking back on the top stories in dermatology from the month of April.

Explore the top headlines of the week including insights on recalls, expert pearls, and more.

This review of the latest dermatologic studies includes insights into the environmental impact of dermatology, submicrobial dosing of antibiotics in dermatology, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dermatology Times is recapping our exclusive expert interviews from the month of April.

The innovative 21-item Hair & Scalp CARE questionnaire is designed to evaluate the psychological impact of hair and scalp conditions on quality of life.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Learn more about the in-depth topics covered in the April 2025 print issue of Dermatology Times.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about the future of regenerative aesthetics, biologic therapies for bullous pemphigoid, phase 3 trial results for Qtorin 3.9% rapamycin gel, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dermatology undergoes rapid transformation with new therapies, but faces challenges in payment reform, certification awareness, and balancing technology with patient care.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Paller discusses the promising phase 3 trial SELVA trial results for Qtorin 3.9% rapamycin gel, an investigative treatment for microcystic lymphatic malformations.

Complete remission was achieved in over 87% of dupilumab users and 64% of omalizumab users.

This review of the latest dermatologic studies includes insights into epidermolysis bullosa for primary care providers, patient-reported impact of atopic dermatitis on pediatric and adolescent patients, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Palvella has secured its 5th US patent for Qtorin rapamycin, extending intellectual property coverage to 2038 and advancing treatment for microcystic lymphatic malformations.

A survey by LEO Pharma indicates widespread misunderstandings about chronic hand eczema, revealing significant emotional and occupational challenges for patients.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about HyBryte's treatment success in CTCL patients, the impact of the COVID-19 pandemic on BCC surgeries, the FDA approval of dupilumab for H1 antihistamine-refractory CSU, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.

Spearheaded by John Zampella, MD, FAAD, and Mitchell Hanson, the project highlights how art can foster community and empathy in dermatology.